1 / 13

GOUT

GOUT . Definition. Heterogeneous group of diseases involving : An elevated serum urate concentration (hyperuricemia) Recurrent attacks of acute arthritis in which monosodium urate monohydrate crystals are demonstrable in synovial fluid leukocytes

jud
Télécharger la présentation

GOUT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GOUT

  2. Definition Heterogeneous group of diseases involving : • An elevated serum urate concentration (hyperuricemia) • Recurrent attacks of acute arthritis in which monosodium urate monohydrate crystals are demonstrable in synovial fluid leukocytes • Aggregates of sodium urate monohydrate crystals (tophi) deposited chiefly in and around joints, which sometimes lead to deformity and crippling • Renal disease involving glomerular, tubular, and interstitial tissues and blood vessels • Uric acid nephrolithiasis Hyperuricemia : serum uric acid >7mg% (males) and >6mg% (females)

  3. Epidemiology • Prevalence of hyperuricemia 2.3 – 41.4% in various populations. Corresponds with serum creatinine /BUN levels, body weight, height, age, blood pressure, and alcohol intake. (Taiwan) Body bulk (as estimated by body weight, surface area, or body mass index) has proved to be one of the most important predictors of hyperuricemia in people of widely differing races and cultures. • Incidence of Gout Varies depending on population studied – 1.8 /1000 – 3.2/1000 RR for blacks slightly higher (1.3)

  4. 1977 ACR criteria for acute gout • The presence of characteristic urate crystals in the joint fluid, or a tophus proved to contain urate crystals by chemical means or polarized light microscopy, or the presence of 6 of the following 12 clinical, laboratory, and radiographic phenomena: • 1. More than one attack of acute arthritis • 2. Maximum inflammation developed within 1 day • 3. Monoarthritis attack • 4. Redness observed over joints • 5. First metatarsophalangeal joint painful or swollen • 6. Unilateral first metatarsophalangeal joint attack • 7. Unilateral tarsal joint attack • 8. Tophus (proven or suspected) • 9. Hyperuricemia • 10. Asymmetric swelling within a joint on x ray/exam • 11. Subcortical cysts without erosions on x ray • 12. Monosodium urate monohydrate microcrystals in joint fluid during attack • 13. Joint fluid culture negative for organisms during attack

  5. Primary Hyperuricemia and Gout with No Associated Condition Uric acid undersecretion(80%–90%) Idiopathic Urate overproduction (10%–20%) Idiopathic HGPRT deficiency PRPP synthetase overactivity Secondary Hyperuricemia and Gout with Identifiable Associated Condition Uric acid undersecretion   Renal insufficiency     Polycystic kidney disease Lead nephropathy    Drugs(Diuretics,Salicylates (low dose), Pyrazinamide, Ethambutol,Niacin, Cyclosporine, Didanosine ) Urate overproduction   Myeloproliferative/ Lymphoproliferative diseases / Hemolytic anemias/ Polycythemia vera/Other malignancies     Psoriasis/Glycogen storage disease Dual mechanism    Obesity, ETOH,Hypoxemia and hypoperfusion Classification of Hyperuricemia and Gout

  6. Outcomes in Gout • Clinical outcomes • 60% of untreated gout have attacks within 1 yr , 78% have recurrence in 2 yrs, only 7% have no attacks in 10 yrs. • Chronic tophaceous gout develops after 10 -20 yrs of untreated gout. Incidence decreased from 14% in 1949 –> 3% in 1972.(Oduffy et al)------’colchicine’ effect’ • Hyperuricemia control superior to self medication alone. • Humanistic outcomes • Treatment outcomes decrease QOL in pts with gout. • Adherence to allopurinol only 56%. (Riedel et al , managed care study) • Economic outcomes • Direct burden annually is 27.4 million USD. (men only) • Patients with acute gout miss 3-5 days of work annually. • Average cost-effectiveness ratio for patients using urate-lowering drugs is $487 to $983 compared with a cost of $5070 to $6571 for those not using these agents.

  7. Diagnosis • Clinical : • In men , initial attack monoarticular – 1st MTP joint(50% of cases) Other jts involved – instep/knees/wrists/ olecranon bursa. Often begins at night. Usually abrupt , severely painful. • Later attacks – polyarticular , assoc with systemic signs., most often initial presenting complaint in women. (hands/tarsal jts/knees) • Precipitants – Minor trauma , ETOH, diuretic Rx, Surgery, severe medical illness, hypouricemic Rx. • Tophi – Classically , helix/ antihelix ,but rare ; more common , hands, feet, olecranon bursa. Complications : ulceration/infection. • Laboratory:- GOLD STANDARD • SF Analysis – WBC ct – 2000-100 000/ml MSU crystals- needle shaped , negatively birefringent. • Serum Uric acid level – important in monitoring treatment .(42% - normal levels) • 24 hr uric acid collection –useful in young pts with gout/ + fam h/o

  8. Diagnosis • Radiologic • X RAY : • Punched out erosions – only 45% of pts have them, takes 6 yrs to develop • Martel’s sign • CT/MRI/US/Bone scan • Sensitive , non specific

  9. Treatment • Acute gouty arthritis: • Anti- inflammatory drugs ( if s.creat < 2mg/dl, no PUD) • Colchicine preferred in pts without confirmed diagnosis of gout. • Endpoints – improvement in jt symptoms/ GI symptoms/ 10 doses taken. • NSAIDs if diagnosis confirmed. Any NSAID can be used . • Newer agents – Etoricoxcib 120 OD comparable to indomethacin 50 TID. • In c/o renal failure /PUD - IM ACTH , oral /iv prednisone. • Avoid adjusting dosage of urate lowering agents. • Prophylaxis : • Only indicated if patient is started on urate lowering Rx. • Colchicine( 1-3 pills a day)/ NSAID( in colchicine intolerant). • Does not alter crystal deposition and development of tophi. • Continue till serum urate levels stabilize and no attacks for 3 – 6 mths. • If long term prophylactic colchicine given, check CBC ,CK every 6 mths.

  10. Treatment (contd) • Control of hyperuricemia • Differing opinions regarding initiation esp. around 1st attack. • Clear evidence if erosions + on X-ray / chronic tophaceous gout/ >2 gout attacks per year. • Goal : s. urate levels < 6 mg%. • Serial s. uric acid at least once every 6 mths upon initiation. • Choice of agents : • Xanthine oxidase inhibitor • Uricosuric agents. • Equal efficacy in pts with normal renal function and who excrete < 800 mg/day of uric acid.

  11. Treatment (contd) • Xanthine oxidase inhibitors • Allopurinol- only prescription drug available. • Renally excreted, therefore adjust dose if s.creat > 2mg% or CrCl <50 • Usually DOC in most patients. • S/E – GI / rash / sarcoid like reaction/Allopurinol hypersensitivity syndrome • Drug interaction – esp. with 6 MP/azathioprine/ warfarin/theophylline. • Desensitization protocols exist. • Oxypurinol – possible option • Uricosuric agents • Indications – no h/o renal calculi , pts <60 yrs, U.A excretion < 800 mg/d • CI - + nephrolithiasis, renal insufficiency • Limit ASA to 81 mg/day • Probenecid/ Benzbromarone

  12. Treatment (contd) • Adjuvant Rx • Control obesity ,ETOH intake, hyperlipidemia ,HTN • Losartan / fenofibrate – weakly uricosuric • Diet – moderation in purine intake. Makes a difference of up to 1mg % in s. uric acid. • Beer, other alcoholic beverages. • Anchovies, sardines in oil, fish roes, herring. • Yeast. • Organ meat (liver, kidneys, sweetbreads) • Legumes (dried beans, peas) • Meat extracts, consommé, gravies. • Mushrooms, spinach, asparagus, cauliflower

  13. Treatment (contd) • Newer agents • PEG- uricase • Febuxostat • Asymptomatic hyperuricemia • Investigate cause • No recommendations for Rx.

More Related